Sunday, April 28, 2024
4/28/2024
In this Yr16 renewal of our longitudinal study on the natural progression of AD biomarkers, the central goal remains to further understand the occurrence of asymptomatic amyloid-beta (Aß) and tau deposition and the progression to clinical cognitive impairment. This cohort has now matured to the point that there is now sufficient longitudinal follow-up to address important hypotheses that were formulated from the beginning of this study but could not be properly addressed until 10-15 years of follow-up were in place - as is the case now. In this renewal period we aim to better characterize the different roles gray matter brain aging and small vessel disease have on AD progression. Chronological age is the most salient risk factor for late-onset AD. However, it remains unclear what components of the aging process account for this risk. In this proposal, we use gray matter brain age models to study the atrophy-related components of aging and 7T vascular imaging to characterize the SVD components of aging. Aim 1 uses this estimated gray matter brain age to explain individual differences in AD biomarkers and cognitive decline. Aim 2 uses fMRI and cerebrovascular imaging at 7T to examine the role of SVD in accelerating the amyloid-induced tauopathy and neurodegeneration. Aim 3 ties together brain aging and SVD to test components of a model that small vessel disease (SVD) accelerates Tau deposition and neurodegeneration (including accelerated gray matter brain aging). Over the last 2 years we have transitioned the MR imaging of this study to a 7T MR scanner to take advantage of its high field strength for 1) characterizing small vessel morphology (e.g., early markers of cerebrovascular disease) associated with AD risk and 2) characterizing functional neural systems (fMRI). Over the course of this study we have shown that many (~25%) of cognitively unimpaired older adults have significant cerebral amyloid deposition, subsequently defined as preclinical AD. We and others have shown that in this preclinical stage, cross-sectional Ab burden is only weakly associated with objective cognitive performance. At this early disease stage, Ab burden is more strongly associated with changes in the functional connectivity, which can be measured by fMRI. We and others have identified that regional medial temporal lobe functional connectivity (MTL_FC) during memory encoding is associated with increased Ab load. In recent preliminary work, we have found that traditional markers of SVD interact with amyloid burden in their relationship to MTL_FC. Those with high Ab and high White Matter Hyperintensity (WMH) burden have particularly high regional MTL_FC. In individuals with Ab burden, SVD accelerates tau deposition, neurodegeneration, and progression of cognitive and clinical decline. The current cohort of 70 active participants will be supplemented by recruitment of additional older adults to achieve 200 baseline assessments. Individuals will undergo 3 MRI scans and 2 Ab- and tau-PET scans over a 32-month interval.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
